BioSpace News Archive

NS Pharma is pleased to announce participation in the Muscular Dystrophy Association’s Clinical & Scientific Congress 2023 being held in Dallas, Texas. The company will be presenting previously reported long-term efficacy and safety data from the open-label extension of a Phase 2 study of VILTEPSO®.

Novartis presented new data which underscore the transformational and sustained benefit of Zolgensma®, an essential one-time gene therapy for the treatment of spinal muscular atrophy.

Leading global biotechnology company Amgen and NSG BioLabs, Singapore’s largest and leading provider of biotechnology co-working laboratories and offices, announced Albatroz Therapeutics as the winner of the first Amgen Golden Ticket in Singapore.

Kangpu Biopharmaceuticals, a clinical-stage company based in Shanghai, China, announced that the Company has completed patient enrollment for the Phase IIa clinical trial of KPG-818 aimed at the treatment of systemic lupus erythematosus in the US.

New data from Daiichi Sankyo’s patritumab deruxtecan from two early trials in patients with previously treated EGFR-mutated metastatic non-small cell lung cancer or HER3 expressing metastatic breast cancer were presented during two Presidential Sessions at the Japanese Society of Medical Oncology Annual Meeting.

Eisai Co., Ltd. announced the publication of updated results from an evaluation estimating the societal value of anti-amyloid-beta protofibril* antibody lecanemab in people living with mild cognitive impairment due to Alzheimer’s disease and mild AD using data from the Phase 3 clinical study, Clarity AD by applying a validated disease simulation model.